Leerink Partners Reiterates Buy Rating for REGENXBIO Inc.
Leerink Partners keeps its buy rating on REGENXBIO with an $18 price target, a 80.54% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on REGENXBIO Inc. (RGNX) with an $18 price target on June 22, 2026.
- Leerink Partners's $18 price target implies 80.54% upside from REGENXBIO Inc.'s ($RGNX) current $9.97 share price.
- Shares of RGNX traded near $7.80 on Tuesday, with a market cap of about $468.9 million and a beta of 1.027.
- Multiple analysts, including Baird and HC Wainwright & Co., also maintain buy ratings with varying targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Leerink Partners has reiterated its buy rating for REGENXBIO Inc. (NasdaqGS: RGNX), setting a price target of $18. This reaffirmation came on June 22, 2026, as the stock traded near $7.80 on Tuesday.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
REGENXBIO Inc. Stock Up 3.2%
Shares of REGENXBIO Inc. were trading around $7.80 on Tuesday. The company, with a market cap of approximately $468.9 million, operates in the biotechnology industry. It has a forward P/E ratio that is not meaningful due to lack of profitability, and a beta of 1.027, indicating moderate volatility. The stock's 52-week range spans from $5.46 to $16.19, with a 50-day moving average of $7.95 and a 200-day moving average of $10.34. The company holds a current ratio of 2.623 and a quick ratio of 2.445, but has a high debt-to-equity ratio of 1178.237.
$RGNX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
REGENXBIO reported revenue of $87.8 million, but faced a revenue decline of 92.8%. The company is not currently profitable, with a negative return on equity of -196.433% and no net margin. The next earnings report is due on August 6, 2026.
Insider Buying and Selling at REGENXBIO Inc.
Several insiders at REGENXBIO made purchases on May 29, 2026. Daniel Tasse, Kenneth Mills, and David Stump each bought 46,600 shares, while Kenneth Mills, Allan Fox, and Alexandra Glucksmann acquired an additional 9,807 shares each. These transactions were not part of any pre-arranged trading plans.
Analysts Set New Price Targets
On June 22, 2026, Baird maintained its buy rating on REGENXBIO with a $32 price target. The same day, Leerink Partners reiterated its buy rating with an $18 target. HC Wainwright & Co. had previously maintained a buy rating with a $26 target on June 5, 2026. The consensus among analysts is a buy rating, with an average target price of $23.82, based on 11 opinions.
About REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company based in Rockville, Maryland, focusing on developing gene therapies for genetic disorders. Using its NAV Technology Platform, the company aims to deliver functional genes to cells with genetic defects. Its pipeline includes treatments for conditions such as wet age-related macular degeneration and Duchenne muscular dystrophy. Founded in 2008, the company also licenses its technology to other biotech and pharmaceutical firms.
Bottom Line
Leerink Partners' reiteration of its buy rating with an $18 target reflects continued confidence in REGENXBIO's potential. Investors often track these analyst ratings for insights into a company's future prospects. However, it's important to remember that these ratings are based on past data and market conditions.
Get REGENXBIO Inc. alerts
New 13F filings, insider trades, and analyst moves on $RGNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.